Amyopathic dermatomyositis

Summary

Amyopathic dermatomyositis (MONDO:0043317) is a disease and 1 clinical trial. Top therapeutic interventions include emapalumab. A subtype of clinically amyopathic dermatomyositis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	amyopathic dermatomyositis
Mondo ID	MONDO:0043317
MeSH	C538250
Orphanet	645617
ICD-11	727262285
SNOMED CT	238935002
UMLS	C0406645
MedGen	96065
GARD	0009907
Is cancer (heuristic)	no

Also known as: ADM · amyopathic dermatomyositis · dermatomyositis sine myositis

Disease family

This is a subtype of clinically amyopathic dermatomyositis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › dermatomyositis › clinically amyopathic dermatomyositis › amyopathic dermatomyositis

Related subtypes (1): hypomyopathic dermatomyositis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07486869	PHASE2	NOT_YET_RECRUITING	Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EMAPALUMAB	4	1